Redefining Sepsis Therapy Through Precision Filtration
SepThera's proprietary reverse-dialysis technology aims to remove harmful immune mediators from the bloodstream, offering an innovative approach to sepsis treatment.
SepThera's Proprietary Filtration Technology
The Sepsis Crisis
Sepsis affects 49 million people globally each year, with a mortality rate of 20-40%. Current treatments are limited and often ineffective.
11 Million Deaths
Sepsis claims approximately 11 million lives annually, making it a leading cause of death worldwide.
$62 Billion Annual Cost
In the US alone, sepsis treatment costs exceed $62 billion annually, representing a significant healthcare burden.
Limited Treatment Options
Current treatments focus on antibiotics and supportive care, but fail to address the harmful immune response.
Precision Immune Mediator Filtration
SepThera is developing an extracorporeal therapy that uses a proprietary reverse-dialysis process designed to selectively remove harmful immune mediators from the bloodstream, addressing the root cause of sepsis progression.
- Selective removal of cytokines and inflammatory mediators
- Preservation of beneficial immune components
- Compatible with existing hospital infrastructure
- Potential to significantly improve patient outcomes
How Our Technology Works
SepThera's proprietary process is designed to selectively filter harmful immune mediators while preserving beneficial components.
Blood Extraction
Blood would be drawn from the patient through a standard vascular access catheter, similar to dialysis.
Potential Advantages
Our approach could offer significant advantages over current sepsis treatments.
Targeted Approach
Our technology aims to directly address the inflammatory cascade that drives sepsis progression.
Potential for Faster Recovery
By removing harmful mediators, patients may experience faster resolution of organ dysfunction.
Reduced ICU Time
Treatment could lead to shorter ICU stays, reducing healthcare costs and improving outcomes.
Complementary Therapy
Designed to work alongside antibiotics and other treatments to provide comprehensive care.
Broad Applicability
Potential effectiveness across different sepsis etiologies and patient populations.
Minimal Side Effects
Selective filtration could minimize adverse effects compared to systemic immunomodulatory approaches.
Join Us in Transforming Sepsis Care
SepThera represents a significant opportunity in the $25+ billion sepsis treatment market. Our technology addresses a critical unmet need with strong IP protection and a clear development pathway.
- Addressing a significant unmet medical need
- Clear regulatory pathway
- Developing partnerships with medical institutions
Get in Touch
Schedule a meeting with our team
Schedule a Meeting with Dr. Felder
Book a consultation to discuss SepThera's innovative sepsis treatment technology